摘要
目的综合分析口服中成药联合羟苯磺酸钙(CD)治疗非增殖型糖尿病视网膜病变(NPDR)的效果和安全性。方法检索从建库至2023年3月26日中外数据库(中国知网、万方、维普、Sinomed、PubMed、Cochrane Library、Embase)中口服中成药治疗NPDR的随机对照试验。依据Cochrane Risk of Bias(ROB)1.0工具进行质量评价,使用ADDIS 1.16.8及Stata 15.0软件统计分析数据并绘制相关图形。结果网状meta分析结果显示临床总有效率疗效排序为:复方丹参滴丸联合CD>芪明颗粒联合CD>复方血栓通胶囊联合CD>双丹明目胶囊联合CD>单用CD;中成药联合CD的不良反应均比单独使用CD少。结论口服中成药联合CD治疗NPDR的临床疗效优于单用CD,且安全性更佳,但受到研究质量及数量限制,望日后得到更多高质量研究佐证。
Objective To comprehensively analyze the efficacy and safety of oral administration of Chinese patent medicines with calcium dobesilate(CD)in the treatment of nonproliferative diabetes retinopathy(NPDR).Methods Randomized controlled trials of oral administration of Chinese patent medicines with calcium dobesilate in the treatment of NPDR in the Chinese and foreign databases(CNKI,Wanfang,VIP,Sinomed,PubMed,Cochrane Library,Embase)from the establishment of the database to March 26,2023 were retrieved.Quality evaluation was conducted using the Cochrane Risk of Bias(ROB)1.0 tool,and data was statistically analyzed using ADDIS1.16.8 and Stata15.0 software,and relevant graphs were drawn.Results The results of the network meta-analysis showed that the overall clinical effective rate of efficacy ranked as follows:compound Danshen dripping pills combined with CD>Qiming granules combined with CD>compound Xueshuantong capsules combined with CD>Shuangdan Mingmu capsules combined with CD>CD alone.The adverse reactions of Chinese patent medicines combined with CD were less than those of CD alone.Conclusion The clinical efficacy of oral administration of Chinese patent medicines combined with CD in the treatment of NPDR is better than that of CD alone,and the safety is better.However,it is limited by the quality and quantity of research,and we hope to get more high-quality research evidence in the futur e.
作者
朱梦霞
彭思萍
吴宗壁
刘德亮
张琳琳
徐明明
ZHU Mengxia;PENG Siping;WU Zongbi;LIU Deliang;ZHANG Linlin;XU Mingming(The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine,Guangdong,Shenzhen 518033,China;Department of Nursing,Shenzhen Traditional Chinese Medicine Hospital,Guangdong,Shenzhen 518033,China;Department of Endocrinology,Shenzhen Traditional Chinese Medicine Hospital,Guangdong,Shenzhen 518033,China)
出处
《中国医药科学》
2024年第8期160-163,共4页
China Medicine And Pharmacy
基金
深圳市中医重点专科建设项目(深卫健中医〔2019〕22号)
深圳市科技计划项目(JCYJ20210324111212033)
深圳市中医院2021年度“3030”计划中医临床研究项目(G3030202123)。
作者简介
通讯作者:徐明明。
